KMT2A Gene Rearrangement clinical trials at UC Davis
1 research study open to eligible people
Experimental drug and combination chemotherapy to treat infants with acute lymphoblastic leukemia and KMT2A gene rearrangement
“Does the addition of azacitidine increase the ability of chemotherapy to kill leukemia cells?”
open to all eligible people
This pilot phase II trial studies the side effects of azacitidine and combination chemotherapy in infants with acute lymphoblastic leukemia and KMT2A gene rearrangement. Drugs used in chemotherapy, such as methotrexate, prednisolone, daunorubicin hydrochloride, cytarabine, dexamethasone, vincristine sulfate, pegaspargase, hydrocortisone sodium succinate, azacitidine, cyclophosphamide, mercaptopurine, leucovorin calcium, and thioguanine work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving more than one drug may kill more cancer cells.
Sacramento, California and other locations